|

SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors

RECRUITINGSponsored by Medical University of Graz
Actively Recruiting
SponsorMedical University of Graz
Started2026-01-01
Est. completion2027-07
Eligibility
Healthy vol.Accepted

Summary

A multicenter retrospective cohort analysis in Austria Primary Objective: To assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall response (mRECIST) in HCC (hepatocellular carcinoma). Secondary Objectives: Evaluate whether vaccination within 1 or 3 months affects OS (overall survival) , PFS (Progression free survival)), or TTP (Time to progression); compare outcomes by vaccination status, vaccine type, and prior infection; explore modification by cirrhosis severity and tumor characteristics; and assess safety (irAEs, steroid use, toxicity-related discontinuation).

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years
* Radiologically or histologically confirmed hepatocellular carcinoma
* Treatment with immune checkpoint inhibitor-based therapy (mono- or combination therapy; e.g., atezolizumab/bevacizumab, durvalumab/tremelimumab, nivolumab, pembrolizumab)
* Complete electronic medical records available
* At least one imaging-based response assessment using mRECIST

Exclusion Criteria:

* Missing key clinical data required for main analyses (e.g. survival status, date of progression, Child-Pugh class, BCLC stage)

Conditions6

CancerCheckpoint InhibitorHepatocellular CarcinomaLiver CancerLiver DiseasemRNA Vaccination

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.